Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00040274 · ClinicalTrials.gov registry record · Phase 1
A Study of DPC 817 in HIV-Infected Males
A Phase 1 study, sponsored by Pharmasset.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00040274: Completed Phase 1 study, sponsored by Pharmasset.
NCT00040274 is a Phase 1 study that has completed, run by Pharmasset. The registered enrollment target is 30 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00040274, a Phase 1 study, has completed, sponsored by Pharmasset.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.
Interventions
- DRUG DPC 817
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 1 |
What the finished NCT00040274 record still lists
NCT00040274 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (50% lower).
The record links to 0 conditions, and to 1 intervention - of which DPC 817 is the first listed.
NCT00040274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00040274 about?
NCT00040274 is a clinical study titled "A Study of DPC 817 in HIV-Infected Males". The purpose of this study is to evaluate DPC 817. The safety, dosages, and how the body responds to the drug will be studied.
What is the current status of trial NCT00040274?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants.
What interventions are being tested in trial NCT00040274?
The interventions under investigation include: DPC 817 (DRUG).
Who is sponsoring clinical trial NCT00040274?
This trial is sponsored by Pharmasset, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00040274's enrollment target sits among peer trials
30 1332nd of 2000 higher than 561 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer